Our Pricing

Wegovy Maintenance Dose: Real UK Weight Loss Results

Published on: June 03, 2026

Understanding wegovy maintenance dose results UK patients experience is essential for long-term weight management success. At Cured Pharmacy, we've supported thousands of patients through their Wegovy journey, from initial titration to sustained maintenance at 2.4mg weekly. Clinical evidence demonstrates that the maintenance phase delivers continued weight loss and metabolic benefits when combined with lifestyle modifications.

What Is the Wegovy Maintenance Dose?

The Wegovy maintenance dose is 2.4mg of semaglutide administered once weekly via subcutaneous injection. After a 16-week dose escalation schedule starting at 0.25mg, patients reach this therapeutic maintenance dose designed for long-term weight management [1]. This gradual titration minimises gastrointestinal side effects whilst allowing your body to adapt to semaglutide's appetite-suppressing mechanisms.

Once you reach the 2.4mg maintenance dose, clinical guidance from the MHRA and NICE recommends continuing at this level indefinitely, provided you're experiencing clinical benefit and tolerating the medication well [2]. The maintenance phase is not a temporary measure—it represents ongoing pharmacological support for weight regulation, similar to how blood pressure medications work long-term.

Clinical Trial Evidence: STEP Programme Results

The STEP clinical trial programme provides robust evidence for wegovy maintenance dose results UK prescribers rely upon when recommending treatment. In the landmark STEP 1 trial, participants maintained on semaglutide 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. Critically, weight loss continued throughout the maintenance phase rather than plateauing after initial months.

STEP 4 examined what happens when patients discontinue maintenance treatment. Participants who stopped semaglutide after 20 weeks regained two-thirds of their lost weight within 48 weeks, whilst those continuing maintenance preserved their weight loss and achieved further modest reductions [3]. This demonstrates that the maintenance dose provides ongoing therapeutic benefit beyond initial weight loss.

Real-World UK Patient Outcomes

Whilst clinical trials operate under controlled conditions, real-world evidence from UK patients mirrors these findings. Our clinical team at Cured Pharmacy, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), observes that patients who adhere to their maintenance dose alongside dietary modifications typically maintain 12-16% body weight reduction after one year. Individual results vary based on baseline weight, adherence, lifestyle factors, and metabolic response to semaglutide.

How Long Should You Stay on Wegovy Maintenance Dose?

Current UK clinical guidance supports indefinite continuation of the wegovy maintenance phase for patients experiencing sustained benefit. The MHRA licence does not specify a maximum treatment duration, and emerging evidence suggests that semaglutide's metabolic benefits—including improved glycaemic control, blood pressure, and lipid profiles—persist only whilst taking the medication [2][4].

Your UK prescriber will conduct regular reviews (typically every 3-6 months) to assess treatment response, tolerability, and ongoing clinical need. If you've maintained stable weight loss for an extended period and wish to attempt discontinuation, this should be done gradually under medical supervision with a clear plan for dietary management and monitoring for weight regain.

Treatment Response Criteria

NICE guidance recommends continuing Wegovy only if you achieve at least 5% body weight loss after 6 months of treatment, including the dose escalation phase [2]. If you haven't reached this threshold, your prescriber may reassess whether semaglutide is the most appropriate option or whether alternative weight management strategies should be considered. At the maintenance dose, most responsive patients continue losing weight gradually or maintain their achieved reduction.

Wegovy Maintenance Dose Results UK: What to Expect

During the maintenance phase at 2.4mg weekly, UK patients typically experience sustained appetite suppression, reduced food cravings, and earlier satiety signals. Weight loss velocity slows compared to the initial titration months, but continued gradual reduction of 0.5-1kg monthly is common in the first year [1]. After 12-18 months, most patients reach a stable weight plateau representing their new metabolic set point whilst on treatment.

Beyond weight reduction, the maintenance dose delivers meaningful improvements in obesity-related comorbidities. Clinical trials demonstrated reductions in waist circumference averaging 13.5cm, improvements in blood pressure, and favourable changes in lipid profiles [1]. Type 2 diabetes risk factors improved significantly, with HbA1c reductions observed even in participants without diagnosed diabetes.

Managing Side Effects During Maintenance

Gastrointestinal side effects—including nausea, diarrhoea, and constipation—are most common during dose escalation but typically diminish once you've been stable on the 2.4mg maintenance dose for several weeks [1]. If side effects persist or worsen during maintenance, your prescriber may temporarily reduce your dose to 1.7mg before re-attempting escalation, or consider whether Wegovy remains suitable for you.

Practical strategies that UK patients find helpful during maintenance include taking your injection on the same day each week (consistency helps manage side effects), staying well-hydrated, eating smaller frequent meals rather than large portions, and avoiding high-fat foods that can exacerbate nausea. Our clinical team at Cured Pharmacy provides ongoing support throughout your maintenance journey to optimise tolerability and outcomes.

When to Contact Your Prescriber

Seek medical advice if you experience persistent vomiting preventing adequate hydration, severe abdominal pain (particularly if radiating to your back, which may indicate pancreatitis), signs of gallbladder problems, or sudden vision changes. Whilst serious adverse events are uncommon, prompt assessment ensures your safety during long-term maintenance treatment. Never adjust your dose without consulting your UK prescriber first.

Starting Wegovy at Cured Pharmacy

Wegovy is available at Cured Pharmacy from £79.00, with transparent upfront pricing shown before your free online consultation. All patients require clinical assessment by a UK-registered prescriber who will evaluate your suitability for semaglutide, review your medical history, and determine the appropriate treatment plan including dose escalation schedule and maintenance phase guidance.

Our consultation takes under 3 minutes to complete online, and if approved, your medication is dispensed by our UK-registered pharmacy (GPhC 9012511) with discreet next-day delivery available. We supply only genuine UK-licensed Wegovy pens, and our clinical team remains available throughout your treatment for dosing queries, side effect management, and ongoing support as you progress through to maintenance.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
3. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
4. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
5. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
7. Torgerson, J. S., et al. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence, baseline weight, and lifestyle modifications. Wegovy is a prescription-only medicine licensed by the MHRA for chronic weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities.